|
US3228601A
(en)
|
1964-02-20 |
1966-01-11 |
Monarch Marking Systems Inc |
Controls for marking machine
|
|
US3536809A
(en)
*
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
*
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
*
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
US3916899A
(en)
*
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
US4008719A
(en)
*
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
US4551177A
(en)
|
1984-04-23 |
1985-11-05 |
National Starch And Chemical Corporation |
Compressible starches as binders for tablets or capsules
|
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
|
US5391485A
(en)
*
|
1985-08-06 |
1995-02-21 |
Immunex Corporation |
DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
|
|
JPS63500636A
(ja)
*
|
1985-08-23 |
1988-03-10 |
麒麟麦酒株式会社 |
多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
|
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
|
US5974203A
(en)
|
1988-04-11 |
1999-10-26 |
Canon Kabushiki Kaisha |
Pattern recognition communication apparatus for transmitting and receiving image data
|
|
US5073543A
(en)
*
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
US5288487A
(en)
*
|
1989-02-28 |
1994-02-22 |
Morinaga Milk Industry Co., Ltd. |
Human monocyte-macrophage-CSF preparations
|
|
IT1229203B
(it)
*
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
|
US5354690A
(en)
*
|
1989-07-07 |
1994-10-11 |
Karl Tryggvason |
Immunological methods for the detection of the human type IV collagen α5 chain
|
|
US5120548A
(en)
*
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
KR0166088B1
(ko)
*
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5733566A
(en)
*
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
AU8868891A
(en)
|
1990-10-12 |
1992-05-20 |
Amgen, Inc. |
Megakaryocyte maturation factors
|
|
AU1531492A
(en)
*
|
1991-02-14 |
1992-09-15 |
Rockefeller University, The |
Method for controlling abnormal concentration tnf alpha in human tissues
|
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
US5358941A
(en)
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
|
US5360352A
(en)
*
|
1992-12-24 |
1994-11-01 |
The Whitaker Corporation |
Wire retainer for current mode coupler
|
|
US5591767A
(en)
*
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US20010056114A1
(en)
*
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US5594637A
(en)
|
1993-05-26 |
1997-01-14 |
Base Ten Systems, Inc. |
System and method for assessing medical risk
|
|
US5698579A
(en)
*
|
1993-07-02 |
1997-12-16 |
Celgene Corporation |
Cyclic amides
|
|
US5641758A
(en)
*
|
1993-11-10 |
1997-06-24 |
Kluge; Michael |
Cytarabine derivatives, the preparation and use thereof
|
|
US6432924B1
(en)
*
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
GB9412394D0
(en)
*
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
|
IT1270594B
(it)
*
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
JPH10508131A
(ja)
|
1994-10-28 |
1998-08-04 |
アドバンスド・ヘルス・メド・イー・システムズ コーポレーション |
処方箋管理システム
|
|
US5593696A
(en)
|
1994-11-21 |
1997-01-14 |
Mcneil-Ppc, Inc. |
Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
|
|
US5619991A
(en)
|
1995-04-26 |
1997-04-15 |
Lucent Technologies Inc. |
Delivery of medical services using electronic data communications
|
|
US5731325A
(en)
|
1995-06-06 |
1998-03-24 |
Andrulis Pharmaceuticals Corp. |
Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
|
|
US5643915A
(en)
*
|
1995-06-06 |
1997-07-01 |
Andrulis Pharmaceuticals Corp. |
Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
|
|
US5832449A
(en)
|
1995-11-13 |
1998-11-03 |
Cunningham; David W. |
Method and system for dispensing, tracking and managing pharmaceutical trial products
|
|
US6063026A
(en)
|
1995-12-07 |
2000-05-16 |
Carbon Based Corporation |
Medical diagnostic analysis system
|
|
DE69740140D1
(de)
|
1996-07-24 |
2011-04-14 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
US5798368A
(en)
|
1996-08-22 |
1998-08-25 |
Celgene Corporation |
Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
|
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US6281230B1
(en)
*
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
FI990180A7
(fi)
*
|
1996-08-12 |
1999-03-08 |
Celgene Corp |
Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi
|
|
US5924074A
(en)
|
1996-09-27 |
1999-07-13 |
Azron Incorporated |
Electronic medical records system
|
|
EP1920773B1
(en)
*
|
1996-11-05 |
2011-01-05 |
The Children's Medical Center Corporation |
Thalidomide and dexamethasone for the treatment of tumors
|
|
US6131090A
(en)
|
1997-03-04 |
2000-10-10 |
Pitney Bowes Inc. |
Method and system for providing controlled access to information stored on a portable recording medium
|
|
US6635280B2
(en)
*
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ATE302597T1
(de)
*
|
1997-06-06 |
2005-09-15 |
Depomed Inc |
Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
|
|
WO1999010829A1
(en)
|
1997-08-22 |
1999-03-04 |
Deka Products Limited Partnership |
Health care system and method for physician order entry
|
|
US5874448A
(en)
*
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
US6096757A
(en)
*
|
1998-12-21 |
2000-08-01 |
Schering Corporation |
Method for treating proliferative diseases
|
|
TR200101500T2
(tr)
*
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
|
|
JPH11286455A
(ja)
|
1998-03-31 |
1999-10-19 |
Kanebo Ltd |
骨髄異形成症候群治療薬
|
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
US6045501A
(en)
|
1998-08-28 |
2000-04-04 |
Celgene Corporation |
Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
|
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
GB9904585D0
(en)
|
1999-02-26 |
1999-04-21 |
Gemini Research Limited |
Clinical and diagnostic database
|
|
WO2000055134A1
(en)
*
|
1999-03-18 |
2000-09-21 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
US20010021380A1
(en)
*
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
KR20020012006A
(ko)
*
|
1999-07-16 |
2002-02-09 |
오오쯔끼쥰조 |
점막 흡수용 글리시리진 제제
|
|
US6202923B1
(en)
|
1999-08-23 |
2001-03-20 |
Innovation Associates, Inc. |
Automated pharmacy
|
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
MXPA02007254A
(es)
*
|
2000-02-04 |
2002-12-09 |
Depomed Inc |
Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
|
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
|
JP4679028B2
(ja)
|
2000-05-15 |
2011-04-27 |
セルジーン コーポレイション |
結腸直腸癌を治療するための組成物および方法
|
|
NZ522767A
(en)
|
2000-05-15 |
2004-07-30 |
Celgene Corp |
Thalidomide and a topoisomerase inhibitor for the treatment of cancer
|
|
AU2001280161A1
(en)
|
2000-08-24 |
2002-03-04 |
Kirin Beer Kabushiki Kaisha |
C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes
|
|
US6315720B1
(en)
|
2000-10-23 |
2001-11-13 |
Celgene Corporation |
Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
|
|
US6458810B1
(en)
*
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
CA2430669C
(en)
|
2000-11-30 |
2011-06-14 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
GB0102342D0
(en)
*
|
2001-01-30 |
2001-03-14 |
Smithkline Beecham Plc |
Pharmaceutical formulation
|
|
JP4361273B2
(ja)
*
|
2001-02-27 |
2009-11-11 |
アメリカ合衆国 |
潜在的な血管形成阻害剤としてのサリドマイド類似体
|
|
DE60231989D1
(de)
*
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
|
US6723340B2
(en)
*
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
JP4027693B2
(ja)
|
2002-03-20 |
2007-12-26 |
トリニティ工業株式会社 |
塗料送給装置及びバルブユニット
|
|
US20030220254A1
(en)
*
|
2002-03-29 |
2003-11-27 |
Texas Tech University System |
Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
|
|
US7498171B2
(en)
*
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
|
DK1505973T3
(da)
|
2002-05-17 |
2010-05-31 |
Celgene Corp |
Kombinationer til behandling af multipelt myelom
|
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
AU2003286836A1
(en)
*
|
2002-10-31 |
2004-06-07 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US20040152632A1
(en)
*
|
2002-11-06 |
2004-08-05 |
Wyeth |
Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
|
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US6943249B2
(en)
*
|
2003-03-17 |
2005-09-13 |
Ash Stevens, Inc. |
Methods for isolating crystalline Form I of 5-azacytidine
|
|
US6887855B2
(en)
*
|
2003-03-17 |
2005-05-03 |
Pharmion Corporation |
Forms of 5-azacytidine
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US20080213213A1
(en)
|
2004-04-14 |
2008-09-04 |
Zeldis Jerome B |
Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
|
|
JP2007532641A
(ja)
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20070155791A1
(en)
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
US8058260B2
(en)
*
|
2006-05-22 |
2011-11-15 |
Xenoport, Inc. |
2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
|
|
US8664272B2
(en)
|
2006-08-30 |
2014-03-04 |
Temple University—Of the Commonwealth System of Higher Education |
Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
|
|
WO2008028193A2
(en)
*
|
2006-09-01 |
2008-03-06 |
Pharmion Corporation |
Colon-targeted oral formulations of cytidine analogs
|
|
JO2778B1
(en)
|
2007-10-16 |
2014-03-15 |
ايساي انك |
Certain Compounds, Compositions and Methods
|
|
US20100311683A1
(en)
|
2007-11-01 |
2010-12-09 |
Beach C L |
Cytidine analogs for treatment of myelodysplastic syndromes
|
|
DK3782612T3
(da)
*
|
2008-05-15 |
2024-01-15 |
Celgene Corp |
Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
|
|
EP3351240B1
(en)
|
2009-05-19 |
2019-04-10 |
Celgene Corporation |
Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
|
|
US9713375B1
(en)
|
2015-02-26 |
2017-07-25 |
Brett Einar Rahm |
Collapsible portable table
|